(Go: >> BACK << -|- >> HOME <<)

Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force Recommendation Statement

Pediatrics. 2009 Apr;123(4):1223-8. doi: 10.1542/peds.2008-2381.

Abstract

Description: This is an update of the 2002 US Preventive Services Task Force recommendation on screening for child and adolescent major depressive disorder.

Methods: The US Preventive Services Task Force weighed the benefits and harms of screening and treatment for major depressive disorder in children and adolescents, incorporating new evidence addressing gaps in the 2002 recommendation statement. Evidence examined included the benefits and harms of screening, the accuracy of primary care-feasible screening tests, and the benefits and risks of treating depression by using psychotherapy and/or medications in patients aged 7 to 18 years.

Recommendations: Screen adolescents (12-18 years of age) for major depressive disorder when systems are in place to ensure accurate diagnosis, psychotherapy (cognitive-behavioral or interpersonal), and follow-up (B recommendation). Evidence is insufficient to warrant a recommendation to screen children (7-11 years of age) for major depressive disorder (I statement).

Publication types

  • Practice Guideline

MeSH terms

  • Adolescent
  • Age Factors
  • Child
  • Depressive Disorder, Major / diagnosis*
  • Depressive Disorder, Major / drug therapy
  • Depressive Disorder, Major / therapy*
  • Health Status Indicators
  • Humans
  • Mass Screening*
  • Neuropsychological Tests
  • Psychotherapy
  • Risk Assessment
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Treatment Outcome

Substances

  • Serotonin Uptake Inhibitors